CSIMarket
 


Painreform Ltd  (PRFX)
Other Ticker:  
 

Painreform Ltd's Quick Ratio

PRFX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2022, Quick Ratio deteriorated to 7.8 a new company low.

Within Major Pharmaceutical Preparations industry 167 other companies have achieved higher Quick Ratio than Painreform Ltd in forth quarter 2022. While Quick Ratio total ranking has improved so far during the IV Quarter 2022 to 539, from total ranking in the third quarter 2022 at 642.

Explain Quick Ratio?
How much Cash & cash equivalents PRFX´s has?
What are PRFX´s Current Liabilities?


PRFX Quick Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Change 31.89 % 31.89 % 31.89 % 31.89 % -
Y / Y Cash & cash equivalent Change -38.5 % -38.5 % -38.5 % -38.5 % -
Quick Ratio MRQ 7.8 7.8 7.8 7.8 16.72
PRFX's Total Ranking # 539 # 642 # 699 # 755 # 382
Seq. Current Liabilities Change 0 % 0 % 0 % 31.89 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -38.5 % 0 %



Quick Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 168
Healthcare Sector # 272
Overall Market # 527


Quick Ratio Statistics
High Average Low
16.72 12.26 7.8
(Dec 31 2021)   (Dec 31 2022)




Financial Statements
Painreform Ltd's Current Liabilities $ 1 Millions Visit PRFX's Balance sheet
Painreform Ltd's Cash & cash equivalent $ 10 Millions Visit PRFX's Balance sheet
Source of PRFX's Sales Visit PRFX's Sales by Geography


Cumulative Painreform Ltd's Quick Ratio

PRFX's Quick Ratio for the trailling 12 Months

PRFX Quick Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities TTM Growth 31.89 % 31.89 % 31.89 % 31.89 % -
Y / Y Cash & cash equivalent TTM Growth -38.5 % -38.5 % -38.5 % -38.5 % -
Quick Ratio TTM 7.8 9.6 11.65 14 16.72
Total Ranking TTM # 4214 # 4107 # 3978 # 3860 # 256
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % 31.89 % 0 %
Seq. Cash & cash equivalent TTM Growth 0 % 0 % 0 % -38.5 % 0 %


  News about Painreform Ltd Quick Ratio

PainReform Secures $4 Million in Public Offering, Fueling Growth in Pharmaceutical Innovation

PainReform's Public Offering Signals Growth in Clinical-Stage Pharmaceutical Industry
In a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of its public offering, marking a significant milestone for the company's growth. The offering includes 5,000,000 of PainReform's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares, with a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant.
The decision to go public with this offering is a strategic move by PainReform to secure necessary funding for their ongoing initiatives in the reformulation of established therapeutics. The proceeds from the offering will support the company's clinical trials and the development of novel treatments, aiming to address unmet medical needs in various therapeutic areas.

PainReform Secures $1.3 Million in Funding through Warrant Exercise, Accelerating Innovation in Drug Pipeline

PainReform Ltd Announces Exercise of Warrants, Garnering Approximately $1.3 Million in Gross Proceeds
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd (Nasdaq: PRFX), a leading clinical-stage specialty pharmaceutical company specializing in the reformulation of established therapeutics, has recently made a significant announcement. The company revealed the immediate exercise of certain outstanding warrants, enabling the purchase of up to 467,896 ordinary shares. These warrants were initially issued by PainReform in July 2023 and will now be exercised at a reduced price of $2.85 per ordinary share, as opposed to the original exercise price of $9.00 per share.
The ordinary shares acquired through the exercise of warrants are registered under an effective registration statement on Form F-1 (File No. 333-274220). The completion of this offering is expected to take place around December 29, 2023, subject to the fulfillment of customary closing conditions.